DOCSLIB.ORG

Autosomal Dominant Leukodystrophy with Autonomic Symptoms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Autosomal Dominant Leukodystrophy with Autonomic Symptoms List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. I MR imaging characteristics and neuropathology of the spin- al cord in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. Sundblom J, Melberg A, Kalimo H, Smits A, Raininko R. AJNR Am J Neuroradiol. 2009 Feb;30(2):328-35. II Genomic duplications mediate overexpression of lamin B1 in adult-onset autosomal dominant leukodystrophy (ADLD) with autonomic symptoms. Schuster J, Sundblom J, Thuresson AC, Hassin-Baer S, Klopstock T, Dichgans M, Cohen OS, Raininko R, Melberg A, Dahl N. Neurogenetics. 2011 Feb;12(1):65-72. III Bedside diagnosis of rippling muscle disease in CAV3 p.A46T mutation carriers. Sundblom J, Stålberg E, Osterdahl M, Rücker F, Montelius M, Kalimo H, Nennesmo I, Islander G, Smits A, Dahl N, Melberg A. Muscle Nerve. 2010 Jun;41(6):751-7. IV A family with discordance between Malignant hyperthermia susceptibility and Rippling muscle disease. Sundblom J, Mel- berg A, Rücker F, Smits A, Islander G. Manuscript submitted to Journal of Anesthesia. Reprints were made with permission from the respective publishers. Contents Introduction..................................................................................................11 Background and history............................................................................... 13 Early studies of hereditary disease...........................................................13 Darwin and Mendel................................................................................. 14 Mendel rediscovered: genetics evolving..................................................14 Eugenics: dark legacy..............................................................................15 Birth of molecular genetics......................................................................16 Human molecular genetics...................................................................... 17 Unfulfilled hopes?................................................................................... 17 Remarks on Medical Genetics......................................................................19 Neurogenetics.............................................................................................. 21 Clinical pointers...................................................................................... 21 Finding disease-causing mutations.......................................................... 22 Types of mutations.................................................................................. 23 Mechanisms affecting pathogenesis........................................................24 Treating neurogenetic disorders...............................................................25 Care and symptomatic relief............................................................... 25 Screening and monitoring................................................................... 25 Replacement/elimination therapy........................................................26 Medical treatment targeting the genetic machinery.............................26 Gene therapy....................................................................................... 27 Cell replacement technology...............................................................28 RNA silencing.....................................................................................28 Translational applications........................................................................ 29 Adult-onset autosomal dominant leukodystrophy with autonomic symptoms (ADLD)........................................................................................................30 Introduction............................................................................................. 30 Genetics...................................................................................................31 Clinical findings ..................................................................................... 31 Differential diagnosis.............................................................................. 32 Molecular mechanisms............................................................................ 35 Treatment options.................................................................................... 36 Rippling muscle disease............................................................................... 38 Introduction............................................................................................. 38 Malignant hyperthermia.......................................................................... 39 Genetics...................................................................................................39 Clinical findings...................................................................................... 40 Differential diagnosis.............................................................................. 41 Molecular mechanisms............................................................................ 42 Treatment options.................................................................................... 43 Aims.............................................................................................................44 Paper I..................................................................................................... 44 Paper II.................................................................................................... 44 Paper III...................................................................................................44 Paper IV.................................................................................................. 44 Methods....................................................................................................... 45 Paper I..................................................................................................... 45 Subjects...............................................................................................45 Magnetic resonance imaging (MRI)....................................................45 Histopathology....................................................................................46 Paper II.................................................................................................... 46 Subjects...............................................................................................46 Duplication analysis............................................................................46 Quantitative reverse transcriptase PCR (qRT-PCR) and western blot analyses of lamin B1 in nucleated blood cells.....................................46 Statistical analysis...............................................................................47 Paper III...................................................................................................47 Subjects...............................................................................................47 Neurophysiological studies................................................................. 48 Muscle pathology................................................................................48 Genetic analysis. ................................................................................ 49 Paper IV.................................................................................................. 49 Results......................................................................................................... 50 Paper I..................................................................................................... 50 Measurements of the spinal cord.........................................................50 Signal intensity of the spinal cord....................................................... 50 Histopathological findings.................................................................. 50 Paper II.................................................................................................... 51 Clinical and neuroradiological features...............................................51 Analysis of gene copy number variation (CNV).................................51 LMNB1 expression ............................................................................ 52 Paper III...................................................................................................52 Clinical investigation.......................................................................... 52 Neurophysiological studies................................................................. 53 Muscle pathology................................................................................53 Genetic analysis.................................................................................. 54 Paper IV.................................................................................................. 55 Discussion.................................................................................................... 56 ADLD......................................................................................................56 RMD........................................................................................................57 Sammanfattning........................................................................................... 59 Acknowledgements...................................................................................... 63 References....................................................................................................66
Load more

Recommended publications
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • The Kid Kit: All You Need to Interview Your Grandparents
    The Kid Kit: All you need to interview your grandparents INCLUDED: • 45 FAMILY HISTORY QUESTIONS • 3 BONUS ACTIVITIES • INTERVIEW RECORDING TIPS • THE HISTORY YOUR GRANDPARENTS LIVED THROUGH • TIPS FOR WHAT TO DO POST-INTERVIEW Recommended for children ages 8-12. Recommended for children A resource from ModernHeirloomBooks.com. ©2020 Modern Heirloom Books LLC. For personal use only. The Kid Kit Dear Grandma/Grandpa/Poppy/Nana/Oma/Bubbe, I can’t wait to interview you and learn more about your life before you were my grandparent. Could you please: • Tell me when you need a break during our interview? • Consider my questions an invitation to tell me everything—don’t feel like you should just answer what I ask, but rather use the questions as a springboard to travel back in time, remember, and tell me all the stories that come to mind—please!! • Have fun! I hope you enjoy this process, and know that I and the rest of the family value you and all that you have experienced. Love, CUT OUT, SIGN & GIVE TO YOUR GRANDPARENT & PARENT BEFORE YOUR INTERVIEW. The Kid Kit Dear Mom/Dad, Thank you for giving me this idea and for helping me to set up my interviews with my grandparent! Could you please: • Let me use one of the family’s smart phones or tablets to record my interviews? I am told that using two might be even better (just in case something goes wrong with one). • Find a few old photos of your parents that I can show them to prompt memories? • Suggest some questions I might ask that you know will spark good stories from your parent(s)? • Help me figure out how to transcribe the interview after it is done? Thank you!! Love, personal use only.
    [Show full text]
  • Adult Onset) an Information Sheet for the Person Who Has Been Diagnosed with a Leukodystrophy, Their Family, and Friends
    Leukodystrophy (Adult Onset) An information sheet for the person who has been diagnosed with a leukodystrophy, their family, and friends. ‘Leukodystrophy’ and the related term ‘leukoencephalopathy’ The person may notice they trip more easily, particularly on refer to a group of conditions that affect the myelin, or white uneven ground or steps. matter, of the brain and spinal cord. Other symptoms that people with adult-onset Leukodystrophies are neurological, degenerative disorders, leukodystrophy may experience include: sensitivity to and most are genetic. This means that a person’s condition extremes of temperature, such as difficulty tolerating hot is caused by a change to one of the genes that are involved summer weather; pain or abnormal sensation, particularly in in the development of myelin, leading to deterioration in the legs; shaking or tremors; loss of vision and/or hearing; many of the body’s neurological functions. The pattern headaches, and difficulty with coordination. of symptoms varies from one type of leukodystrophy to People with leukodystrophy often experience long delays another, and there may even be some variation between before receiving a correct diagnosis. This is partly because different people with the same condition, however all are the symptoms can be quite vague and associated with described as progressive. This means that although there many different disorders. Leukodystrophies are rare, and may be periods of stability, the condition doesn’t go into it is routine medical practice to rule out more common and ‘remission’ as may be seen in some other neurological treatable causes before testing for rarer conditions. There conditions, and over time the condition worsens.
    [Show full text]
  • Child Neurology: Hereditary Spastic Paraplegia in Children S.T
    RESIDENT & FELLOW SECTION Child Neurology: Section Editor Hereditary spastic paraplegia in children Mitchell S.V. Elkind, MD, MS S.T. de Bot, MD Because the medical literature on hereditary spastic clinical feature is progressive lower limb spasticity B.P.C. van de paraplegia (HSP) is dominated by descriptions of secondary to pyramidal tract dysfunction. HSP is Warrenburg, MD, adult case series, there is less emphasis on the genetic classified as pure if neurologic signs are limited to the PhD evaluation in suspected pediatric cases of HSP. The lower limbs (although urinary urgency and mild im- H.P.H. Kremer, differential diagnosis of progressive spastic paraplegia pairment of vibration perception in the distal lower MD, PhD strongly depends on the age at onset, as well as the ac- extremities may occur). In contrast, complicated M.A.A.P. Willemsen, companying clinical features, possible abnormalities on forms of HSP display additional neurologic and MRI abnormalities such as ataxia, more significant periph- MD, PhD MRI, and family history. In order to develop a rational eral neuropathy, mental retardation, or a thin corpus diagnostic strategy for pediatric HSP cases, we per- callosum. HSP may be inherited as an autosomal formed a literature search focusing on presenting signs Address correspondence and dominant, autosomal recessive, or X-linked disease. reprint requests to Dr. S.T. de and symptoms, age at onset, and genotype. We present Over 40 loci and nearly 20 genes have already been Bot, Radboud University a case of a young boy with a REEP1 (SPG31) mutation. Nijmegen Medical Centre, identified.1 Autosomal dominant transmission is ob- Department of Neurology, PO served in 70% to 80% of all cases and typically re- Box 9101, 6500 HB, Nijmegen, CASE REPORT A 4-year-old boy presented with 2 the Netherlands progressive walking difficulties from the time he sults in pure HSP.
    [Show full text]
  • Hereditary Spastic Paraparesis: a Review of New Developments
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.2.150 on 1 August 2000. Downloaded from 150 J Neurol Neurosurg Psychiatry 2000;69:150–160 REVIEW Hereditary spastic paraparesis: a review of new developments CJ McDermott, K White, K Bushby, PJ Shaw Hereditary spastic paraparesis (HSP) or the reditary spastic paraparesis will no doubt Strümpell-Lorrain syndrome is the name given provide a more useful and relevant classifi- to a heterogeneous group of inherited disorders cation. in which the main clinical feature is progressive lower limb spasticity. Before the advent of Epidemiology molecular genetic studies into these disorders, The prevalence of HSP varies in diVerent several classifications had been proposed, studies. Such variation is probably due to a based on the mode of inheritance, the age of combination of diVering diagnostic criteria, onset of symptoms, and the presence or other- variable epidemiological methodology, and wise of additional clinical features. Families geographical factors. Some studies in which with autosomal dominant, autosomal recessive, similar criteria and methods were employed and X-linked inheritance have been described. found the prevalance of HSP/100 000 to be 2.7 in Molise Italy, 4.3 in Valle d’Aosta Italy, and 10–12 Historical aspects 2.0 in Portugal. These studies employed the In 1880 Strümpell published what is consid- diagnostic criteria suggested by Harding and ered to be the first clear description of HSP.He utilised all health institutions and various reported a family in which two brothers were health care professionals in ascertaining cases aVected by spastic paraplegia. The father was from the specific region.
    [Show full text]
  • Hereditary Spastic Paraplegias
    Hereditary Spastic Paraplegias Authors: Doctors Enza Maria Valente1 and Marco Seri2 Creation date: January 2003 Update: April 2004 Scientific Editor: Doctor Franco Taroni 1Neurogenetics Istituto CSS Mendel, Viale Regina Margherita 261, 00198 Roma, Italy. e.valente@css- mendel.it 2Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Università degli studi di Bologna, Laboratorio di Genetica Medica, Policlinico S.Orsola-Malpighi, Via Massarenti 9, 40138 Bologna, Italy.mailto:[email protected] Abstract Keywords Disease name and synonyms Definition Classification Differential diagnosis Prevalence Clinical description Management including treatment Diagnostic methods Etiology Genetic counseling Antenatal diagnosis References Abstract Hereditary spastic paraplegias (HSP) comprise a genetically and clinically heterogeneous group of neurodegenerative disorders characterized by progressive spasticity and hyperreflexia of the lower limbs. Clinically, HSPs can be divided into two main groups: pure and complex forms. Pure HSPs are characterized by slowly progressive lower extremity spasticity and weakness, often associated with hypertonic urinary disturbances, mild reduction of lower extremity vibration sense, and, occasionally, of joint position sensation. Complex HSP forms are characterized by the presence of additional neurological or non-neurological features. Pure HSP is estimated to affect 9.6 individuals in 100.000. HSP may be inherited as an autosomal dominant, autosomal recessive or X-linked recessive trait, and multiple recessive and dominant forms exist. The majority of reported families (70-80%) displays autosomal dominant inheritance, while the remaining cases follow a recessive mode of transmission. To date, 24 different loci responsible for pure and complex HSP have been mapped. Despite the large and increasing number of HSP loci mapped, only 9 autosomal and 2 X-linked genes have been so far identified, and a clear genetic basis for most forms of HSP remains to be elucidated.
    [Show full text]
  • Studies and Sources in Islamic Art and Architecture
    STUDIES AND SOURCES IN ISLAMIC ART AND ARCHITECTURE SUPPLEMENTS TO MUQARNAS Sponsored by the Aga Khan Program for Islamic Architecture at Harvard University and the Massachusetts Institute of Technology, Cambridge, Massachusetts. VOLUME IX PREFACING THE IMAGE THE WRITING OF ART HISTORY IN SIXTEENTH-CENTURY IRAN BY DAVID J. ROXBURGH BRILL LEIDEN • BOSTON • KÖLN 2001 This book is printed on acid-free paper. Library of Congress Cataloging-in-Publication Data Roxburgh, David J. Prefacing the image : the writing of art history in sixteenth-century Iran / David J. Roxburgh. p. cm. — (Studies and sources in Islamic art and architecture. Supplements to Muqarnas, ISSN 0921 0326 ; v. 9) Includes bibliographical references and index. ISBN 9004113762 (alk. papier) 1. Art, Safavid—Historiography—Sources. 2. Art, Islamic—Iran– –Historiography—Sources. 3. Art criticism—Iran—History—Sources. I. Title. II. Series. N7283 .R69 2000 701’.18’095509024—dc21 00-062126 CIP Die Deutsche Bibliothek - CIP-Einheitsaufnahme Roxburgh, David J.: Prefacing the image : the writing of art history in sixteenth century Iran / by David J. Roxburgh. – Leiden; Boston; Köln : Brill, 2000 (Studies and sources in Islamic art and architectue; Vol 9) ISBN 90-04-11376-2 ISSN 0921-0326 ISBN 90 04 11376 2 © Copyright 2001 by Koninklijke Brill NV, Leiden, The Netherlands All rights reserved. No part of this publication may be reproduced, translated, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission from the publisher. Authorization to photocopy items for internal or personal use is granted by Brill provided that the appropriate fees are paid directly to The Copyright Clearance Center, 222 Rosewood Drive, Suite 910 Danvers MA 01923, USA.
    [Show full text]
  • Follow-Up Study of 22 Chinese Children with Alexander Disease and Analysis of Parental Origin of De Novo GFAP Mutations
    Journal of Human Genetics (2013) 58, 183–188 & 2013 The Japan Society of Human Genetics All rights reserved 1434-5161/13 www.nature.com/jhg ORIGINAL ARTICLE Follow-up study of 22 Chinese children with Alexander disease and analysis of parental origin of de novo GFAP mutations Lili Zang1, Jingmin Wang1, Yuwu Jiang1, Qiang Gu1, Zhijie Gao1, Yanling Yang1, Jiangxi Xiao2 and Ye Wu1 To delineate the phenotype and genotype in Chinese children with type I Alexander disease (AxD) and the parental origin of de novo glial fibrillary acidic protein (GFAP) mutations. Twenty-two children with clinically diagnosed type I AxD were followed up for 1.66–6.62 years. Allele-specific PCR was used for the analysis of parental origin of the allele harboring the de novo mutation. Phenotype of these patients were consistent with type I AxD described in other population, with developmental delay (motor delay in 81.82%, cognitive delay in 63.64%), macrocephaly (100%), seizures (95.45%), paroxysmal deterioration (27.27%) and typical brain magnetic resonance imaging (100%). Progression was slower than reported. At 8.55 years of age (5.29–13.25), all patients who underwent the second follow-up were alive. Eleven heterozygous missense mutations of GFAP were identified in 21 patients, with three novel mutations. Reported hot spot mutations, p.R79, p.R239 and p.R88, were also identified in Chinese patients. Mutations were de novo in all but one case. The mother of a proband was demonstrated to be a presymptomatic patient with type II AxD with a p.R79H mutation. Ninety percent of de novo mutations were on the paternal allele demonstrated by allele-specific PCR.
    [Show full text]
  • Infantile Alexander Disease: Case Report and Review of Literature Dentistry Section
    Case Report DOI: 10.7860/JCDR/2017/26875.10106 Infantile Alexander Disease: Case Report and Review of Literature Dentistry Section SOUMYABRATA SARKAR1, RUPAM SINHA2, AMITABHA CHAKRABORTY3, TANYA KHAITAN4, BIYAS BHOWMIK5 ABSTRACT Alexander Disease (AD) is an autosomal dominant leukodystrophy and occurs predominantly in infants and children. It usually results in death within ten years after onset. Among the four subtypes, infantile form comprises the most of affected individuals. It presents in the first two years of life, typically with progressive psychomotor deficiency, loss of developmental milestones, seizures, and pyramidal signs. Clinical and magnetic resonance image findings usually establish diagnosis of AD. Here, we present a case of Infantile AD with characteristic clinical and radiological features. Keywords: Leukodystrophy, Magnetic resonance imaging, Seizures CASE REPORT A five-year-old boy reported to the Department of Oral Medicine and Radiology, with painful decayed tooth in the upper right back jaw region for 10 days. The pain was mild, continuous, non- radiating in nature with no associated factors. The patient’s parents gave history of delayed developmental milestones of their son. There was no history of consanguineous marriage of the patient’s parents. They reported their son to be normal at birth with standard birth weight and head circumference. There was history of seizures six months after birth, with gradual psychomotor deficiencies and cognitive abnormalities, for which his parents sought paediatric consultation immediately at seven months of age. Initial consultation was inconclusive due to lack of diagnostic evidence and financial constrictions. However, he was put on phenytoin oral suspension twice daily, which controlled the symptoms.
    [Show full text]
  • Genetic Status of the Swedish Central Collection of Heirloom Apple Cultivars
    Scientia Horticulturae 272 (2020) 109599 Contents lists available at ScienceDirect Scientia Horticulturae journal homepage: www.elsevier.com/locate/scihorti Genetic Status of the Swedish Central collection of heirloom apple cultivars T Jonas Skytte af Sätraa,*, Michela Troggiob, Firuz Odilbekova, Jasna Sehicc, Helena Mattissona, Inger Hjalmarssond, Pär K. Ingvarssone, Larisa Garkava-Gustavssona a Department of Plant Breeding, Swedish University of Agricultural Sciences, Alnarp, Sweden b Research and Innovation Centre, Fondazione Edmund Mach, San Michele all’Adige, Trento, Italy c Department of Plant Breeding – Balsgård, Swedish University of Agricultural Sciences, Fjälkestadsvägen 459, 29194, Kristianstad, Sweden d Department of Landscape Architecture, Planning and Management, Swedish University of Agricultural Sciences, Alnarp, Sweden e Department of Plant Biology, Swedish University of Agricultural Sciences, 750 07, Uppsala, Sweden ARTICLE INFO ABSTRACT Keywords: Cultivated apple is one of the most widely grown fruit crops worldwide. With the introduction of modern apple Malus domestica cultivars, from foreign and national breeding programs, the use of local cultivars decreased during the 20th SNP array century. In order to minimize genetic erosion and avoid loss of special genotypes, a number of local clonal Genotyping archives were established across Sweden, with the goal of retaining old and local cultivars. About 220 apple Pedigree cultivars, appointed for preservation, obtained the status of mandate cultivars. Initially, they were identified Gene bank based on pomological traits, but prior to the establishment of the Swedish Central Collection they were geno- Local cultivars SSR markers typed with simple sequence repeat (SSR) markers. SSR markers helped to evaluate the status of the preserved material, as well as to find the best possible true-to-type source for propagation, thus guiding the establishment of the Central Collection.
    [Show full text]
  • Blueprint Genetics Leukodystrophy and Leukoencephalopathy Panel
    Leukodystrophy and Leukoencephalopathy Panel Test code: NE2001 Is a 118 gene panel that includes assessment of non-coding variants. In addition, it also includes the maternally inherited mitochondrial genome. Is ideal for patients with a clinical suspicion of leukodystrophy or leukoencephalopathy. The genes on this panel are included on the Comprehensive Epilepsy Panel. About Leukodystrophy and Leukoencephalopathy Leukodystrophies are heritable myelin disorders affecting the white matter of the central nervous system with or without peripheral nervous system myelin involvement. Leukodystrophies with an identified genetic cause may be inherited in an autosomal dominant, an autosomal recessive or an X-linked recessive manner. Genetic leukoencephalopathy is heritable and results in white matter abnormalities but does not necessarily meet the strict criteria of a leukodystrophy (PubMed: 25649058). The mainstay of diagnosis of leukodystrophy and leukoencephalopathy is neuroimaging. However, the exact diagnosis is difficult as phenotypes are variable and distinct clinical presentation can be present within the same family. Genetic testing is leading to an expansion of the phenotypic spectrum of the leukodystrophies/encephalopathies. These findings underscore the critical importance of genetic testing for establishing a clinical and pathological diagnosis. Availability 4 weeks Gene Set Description Genes in the Leukodystrophy and Leukoencephalopathy Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ABCD1*
    [Show full text]
  • Alexander Disease HH 2020 LCN Winter Meeting
    2020 Winter Meeting March 3, 2020 Alexander Disease Speakers • CHOP : Katy McDonald, MSN,CRNP • Family Advocate : De Flohre Alexander Disease Children What is Alexander Disease? • Referred to as ALX, AxD, Demyelinogenic Leukodystrophy, Fibrinoid Leukodystrophy, White Matter Disease, and other names • Alexander Disease is a fatal neurodegenerative disorder that destroys structure and functionality of neurons in the brain • Demyelination caused by lack of Glial Fibrillary Acidic Protein (GFAP) • Only leukodystrophy in which Rosenthal Fibers appear • Rosenthal Fibers are abnormal protein deposits that cause improper cell function Rosenthal fibers Too much GFAP Gain of Mice (couresy of Albee Messing) function protein Morphologically and biochemically identical to human Rosenthal fibers How do you get Alexander Disease? In our cohort at CHOP, • Typically Genetic approximately 90% • 95% of patients have a mutation in GFAP. No other genes have Type I (younger) patients have a de been associated with AxD. novo mutation on • Mosaic parents Chromosome 17 that • Later-onset is classically genetic expresses Glial • autosomal dominant form Fibrillary Acidic Protein (GFAP) GFAP gene How Does Alexander Disease Affect the Individual? • Alexander Disease is a demyelinating disease and causes the loss of many functions such as walking, talking, and eating • Alexander Disease is progressive and causes severe loss of previously attained milestones or failure to thrive in the infantile form What are Initial Symptoms of Alexander Disease? The Different Types of Alexander’ Disease Present Differently Patients with juvenile • alexander’s disease are Macrocephaly sometimes misdiagnosed with • Seizures anorexia due to the severity of • Developmental Delays their failure to thrive and • Vomiting, swallowing or feeding issues feeding issues.
    [Show full text]